These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31488241)

  • 21. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
    Tan PS; Aguiar P; Haaland B; Lopes G
    Lung Cancer; 2018 Jan; 115():84-88. PubMed ID: 29290267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of Halo Nevi in a Lung Cancer Patient: A Novel Immune-Related Cutaneous Event from Atezolizumab.
    Birnbaum MR; Ma MW; Casey MA; Amin BD; Jacobson M; Cheng H; McLellan BN
    J Drugs Dermatol; 2017 Oct; 16(10):1047-1049. PubMed ID: 29036261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma].
    Berghmans T; Grigoriu B; Sculier JP; Meert AP
    Rev Mal Respir; 2018 Feb; 35(2):197-205. PubMed ID: 29395567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients.
    Zhuo M; Chen H; Zhang T; Yang X; Zhong J; Wang Y; An T; Wu M; Wang Z; Huang J; Zhao J
    Cancer Biomark; 2018; 22(3):467-476. PubMed ID: 29758930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pneumonitis From Anti-PD-1/ PD-L1 Therapy.
    Balaji A; Verde F; Suresh K; Naidoo J
    Oncology (Williston Park); 2017 Oct; 31(10):739-46, 754. PubMed ID: 29083466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report.
    Qiu G; Li S; Li B; Yang Q; Deng H; Yang Y; Xie X; Lin X; Seki N; Miura S; Shukuya T; Zhou C; Liu M
    Transl Lung Cancer Res; 2022 Nov; 11(11):2346-2355. PubMed ID: 36519029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
    Leventakos K; Mansfield AS
    BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
    Peters S; Gettinger S; Johnson ML; Jänne PA; Garassino MC; Christoph D; Toh CK; Rizvi NA; Chaft JE; Carcereny Costa E; Patel JD; Chow LQM; Koczywas M; Ho C; Früh M; van den Heuvel M; Rothenstein J; Reck M; Paz-Ares L; Shepherd FA; Kurata T; Li Z; Qiu J; Kowanetz M; Mocci S; Shankar G; Sandler A; Felip E
    J Clin Oncol; 2017 Aug; 35(24):2781-2789. PubMed ID: 28609226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint inhibitors in non-small cell lung cancer - towards daily practice.
    Domagała-Kulawik J
    Adv Respir Med; 2018; 86(3):. PubMed ID: 29960281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.
    Nishino M; Chambers ES; Chong CR; Ramaiya NH; Gray SW; Marcoux JP; Hatabu H; Jänne PA; Hodi FS; Awad MM
    Cancer Immunol Res; 2016 Apr; 4(4):289-93. PubMed ID: 26865455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
    Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atezolizumab for the treatment of non-small cell lung cancer.
    Santini FC; Rudin CM
    Expert Rev Clin Pharmacol; 2017 Sep; 10(9):935-945. PubMed ID: 28714780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
    Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.
    Liu SV; Camidge DR; Gettinger SN; Giaccone G; Heist RS; Hodi FS; Ready NE; Zhang W; Wallin J; Funke R; Waterkamp D; Foster P; Iizuka K; Powderly J
    Eur J Cancer; 2018 Sep; 101():114-122. PubMed ID: 30053670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
    Sgambato A; Casaluce F; Gridelli C
    Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study.
    Gandara DR; von Pawel J; Mazieres J; Sullivan R; Helland Å; Han JY; Ponce Aix S; Rittmeyer A; Barlesi F; Kubo T; Park K; Goldschmidt J; Gandhi M; Yun C; Yu W; Matheny C; He P; Sandler A; Ballinger M; Fehrenbacher L
    J Thorac Oncol; 2018 Dec; 13(12):1906-1918. PubMed ID: 30217492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy-induced pneumonitis: cases report.
    Helber HA; Hada AL; Pio RB; Moraes PHZ; Gomes DBD
    Einstein (Sao Paulo); 2018 Jun; 16(2):eRC4030. PubMed ID: 29947645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer.
    Bordoni R; Ciardiello F; von Pawel J; Cortinovis D; Karagiannis T; Ballinger M; Sandler A; Yu W; He P; Matheny C; Felizzi F; Rittmeyer A
    Clin Lung Cancer; 2018 Sep; 19(5):441-449.e4. PubMed ID: 30017645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.
    Ksienski D; Wai ES; Croteau N; Fiorino L; Brooks E; Poonja Z; Fenton D; Geller G; Glick D; Lesperance M
    Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First Anti-PD-L1 Drug Approved for NSCLC.
    Cancer Discov; 2016 Dec; 6(12):OF1. PubMed ID: 27920140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.